Strong Sales Growth Amid Market Challenges

This article first appeared on GuruFocus.

Release Date: November 05, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

• Novo Nordisk AS (NYSE:NVO) reported a 15% increase in sales and a 10% rise in operating profit for the first nine months of 2025.

• The company has expanded its reach, now serving around 46 million people with diabetes and obesity, an increase of 3 million from the previous year.

• Novo Nordisk AS (NYSE:NVO) is intensifying its focus on core areas such as diabetes and obesity, which is expected to drive future growth.

• The company is undergoing a transformation to simplify its operating model, which is expected to save approximately DKK 8 billion annually by the end of 2026.

• Novo Nordisk AS (NYSE:NVO) is actively pursuing strategic acquisitions, such as the proposed acquisition of Metsera, to enhance its R&D portfolio and address unmet medical needs.

• Novo Nordisk AS (NYSE:NVO) has narrowed its sales growth guidance to 8-11% and operating profit growth to 4-7%, citing lower growth expectations for GLP-1 treatments in diabetes and obesity.

• The company is facing intensifying competition in both diabetes and obesity markets, which is impacting its market share.

• Novo Nordisk AS (NYSE:NVO) plans to reduce approximately 9,000 positions globally as part of its transformation program, which could have a significant human impact.

• The company is experiencing pricing pressure and competition in the US market, particularly affecting its GLP-1 diabetes care products.

• Novo Nordisk AS (NYSE:NVO) is dealing with challenges related to compounded GLP-1 products in the US, which are impacting its market dynamics.

Q: Novo Nordisk has lost 9% market share in the combined obesity and diabetes market over the last 12 months. What strategic initiatives are being considered to address this? A: Mike Duta, CEO, emphasized focusing on expanding the market for diabetes and obesity treatments. This includes launching new products like the Vigoy pill and increasing commercial partnerships with companies like Costco and Walmart. The strategy is to expand the market and ensure more patients receive treatment, acknowledging that these measures will take time to show results.

Q: There are concerns that Novo Nordisk’s pursuit of Metarra indicates a lack of confidence in its internal pipeline. How do you differentiate between Metarra’s assets and Novo’s existing pipeline? A: Mike Duta, CEO, expressed excitement about Novo’s pipeline but emphasized that no pipeline is broad enough to meet the ambition of treating hundreds of millions of people. Metarra’s assets are seen as complementary and differentiated, supporting Novo’s long-term strategy. Martin, EVP of Research and Development, added that Metarra’s assets offer differentiation in terms of efficacy, safety, and dosing frequency.